Brief: Palatin Completes Enrollment Of Phase 2 Study With Pl9643 For Dry Eye Disease
05/08/2020 12:43
Aug 5 (Reuters) - Palatin Technologies Inc PTN.A :
* PALATIN TECHNOLOGIES, INC. ANNOUNCES COMPLETION OF
ENROLLMENT OF
PHASE 2 STUDY WITH PL9643 FOR THE TREATMENT OF DRY EYE DISEASE
* PALATIN TECHNOLOGIES INC - WITH ENROLLMENT COMPLETED, DATA
READOUT IS TARGETED FOR Q4 OF CALENDAR YEAR 2020
Source text for Eikon: ID:nPnc3b4gya
Further company coverage: PTN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity